FEATURED:

Republican chairman wants FTC to review mergers of drug price negotiators

Republican chairman wants FTC to review mergers of drug price negotiators

House Energy and Commerce Committee Chairman Greg WaldenGregory (Greg) Paul WaldenVulnerable Republicans throw ‘Hail Mary’ on pre-existing conditions GOP senator wants Apple, Amazon to give briefing on reported Super Micro hack Overnight Health Care: Bill banning 'gag clauses' on drugs heads to Trump's desk | Romney opposes Utah Medicaid expansion | GOP candidate under fire over ad on pre-existing conditions MORE (R-Ore.) on Friday requested a review of mergers by drug price negotiators, questioning whether the moves had driven up costs for patients.

Walden wrote to the Federal Trade Commission requesting a review looking at recent mergers of companies known as pharmacy benefit managers (PBMs), which negotiate prices with drug manufacturers.

In the letter, Walden said that while there is “conflicting information” on the impact of these mergers, he fears some companies could have “used their market power to try to increase their profits and that PBMs have encouraged higher list prices for prescription drugs that increase co-pays for patients.”

ADVERTISEMENT

The letter comes amid increased scrutiny of high drug prices. President TrumpDonald John TrumpKey takeaways from the Arizona Senate debate Major Hollywood talent firm considering rejecting Saudi investment money: report Mattis says he thought 'nothing at all' about Trump saying he may leave administration MORE has been calling out drug companies by name on Twitter, and his administration recently floated the possibility of allowing the importation of drugs to increase competition when there are price spikes.

The letter from Walden, which was also signed by GOP Reps. Gregg HarperGregory (Gregg) Livingston HarperGOP lawmakers urge improvements to cyber vulnerabilities resource Bipartisan leaders of House panel press drug companies on opioid crisis Republican chairman wants FTC to review mergers of drug price negotiators MORE (Miss.) and Michael BurgessMichael Clifton BurgessCards Against Humanity offering midterm expansion pack in effort to back Dems in key races Overnight Health Care: Bill banning 'gag clauses' on drugs heads to Trump's desk | Romney opposes Utah Medicaid expansion | GOP candidate under fire over ad on pre-existing conditions Twitter’s Dorsey apologizes to McCain family for ‘unacceptable’ tweet MORE (Texas), focuses more on PBMs, which have also come under scrutiny for a lack of transparency in setting prices.

Some drug pricing advocates, however, say the focus should be on drug companies that initially set the prices.